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The outgrowth of Porphyromonas gingivalis within the inflammatory subgingival plaque is associated with periodontitis charac-
terized by periodontal tissue destruction, loss of alveolar bone, periodontal pocket formation, and eventually, tooth loss. Poten-
tial virulence factors of P. gingivalis are peptidylarginine deiminase (PPAD), an enzyme modifying free or peptide-bound argi-
nine to citrulline, and the bacterial proteases referred to as gingipains (Rgp and Kgp). Chemokines attract leukocytes during
inflammation. However, posttranslational modification (PTM) of chemokines by proteases or human peptidylarginine deimi-
nases may alter their biological activities. Since chemokine processing may be important in microbial defense mechanisms, we
investigated whether PTM of chemokines by P. gingivalis enzymes occurs. Upon incubation of interleukin-8 (IL-8; CXCL8) with
PPAD, only minor enzymatic citrullination was detected. In contrast, Rgp rapidly cleaved CXCL8 in vitro. Subsequently, differ-
ent P. gingivalis strains were incubated with the chemokine CXCL8 or CXCL10 and their PTMs were investigated. No significant
CXCL8 citrullination was detected for the tested strains. Interestingly, although considerable differences in the efficiency of
CXCL8 degradation were observed with full cultures of various strains, similar rates of chemokine proteolysis were exerted by
cell-free culture supernatants. Sequencing of CXCL8 incubated with supernatant or bacteria showed that CXCL8 is processed
into its more potent forms consisting of amino acids 6 to 77 and amino acids 9 to 77 (the 6-77 and 9-77 forms, respectively). In
contrast, CXCL10 was entirely and rapidly degraded by P. gingivalis, with no transient chemokine forms being observed. In con-
clusion, this study demonstrates PTM of CXCL8 and CXCL10 by gingipains of P. gingivalis and that strain differences may par-
ticularly affect the activity of these bacterial membrane-associated proteases.
Cytokine and chemokine activity is regulated at multiple levels,including posttranslational modification (PTM) (1–3). Re-
duced or enhanced receptor affinity/specificity and chemokine
activity have been reported, depending on the chemokine and on
the type of PTM (4, 5). Most PTMs on inflammatory chemokine
ligands depend on proteolytic cleavage, with highly specific pro-
teases mainly affecting the NH2-terminal region of the protein (2,
5–7). Many metalloproteases, such as aminopeptidase N/CD13 and
various matrix metalloproteases, and a number of serine proteases,
including thrombin, plasmin, cathepsin G, and the dipeptidylpepti-
dase CD26, were reported to cleave specific chemokines in the NH2-
terminal region. The biological effect of such proteolytic processing
varies dependingon the chemokine andprotease involved. First, lim-
itedNH2-terminalproteolyticprocessingof chemokinesbyproteases
can result in enhanced biological activity, e.g., CXCL8 processing by
thrombin (8, 9) ormatrixmetalloproteinase 9 (MMP-9)/gelatinaseB
(10) and CCL3L1 processing by DPPIV/CD26 (11), or decreased bi-
ological activity, e.g., CCL7 processing by MMP-2/gelatinase A (12)
and CXCL10 processing by CD26 (13). For some chemokines, like
CXCL7andCCL14,more extensiveNH2-terminal truncation is even
mandatory to obtain receptor signaling and chemotactic properties
(14–16). A detailed description of chemokine-protease interactions
and the consequences for the biological functions of chemokines has
been published in a number of recent reviews (2, 5, 6, 17). Also,
naturally occurringN- andO-glycosylated formsof chemokineswith
altered lectin binding properties have been identified (18–20). In ad-
dition to NH2- and COOH-terminal proteolytic processing and gly-
cosylation, citrullination, i.e., deimination of arginine (Arg) to citrul-
line (Cit), is a recently discovered PTM on the natural chemokines
interleukin-8 (IL-8; CXCL8) and gamma interferon-inducible pro-
tein 10 (IP-10; CXCL10) (8, 13, 21–24). CXCL8, a ligand for CXC
chemokine receptors CXCR1 and CXCR2, is known to be themajor
human neutrophil chemoattractant. The CXCR3 ligand CXCL10
predominantly chemoattracts activated lymphocytes. For both
chemokines, Arg at position 5 (Arg5) was converted into Cit. The
mammalianenzymes responsible for theconversionarepeptidylargi-
nine deiminases (PADs) (25). Chemokines were the first identified
PAD substrates that signal in a receptor-dependent manner. Most
other PAD substrates are structural proteins (e.g., keratin and filla-
grin) (26–31). Citrullinationmay considerably influence the biolog-
ical activity of proteins, since itmay change ionic interactions inmac-
romolecules, resulting in altered protein folding, and may cause
altered binding of proteins to other macromolecules, such as DNA,
glycosaminoglycans, and other proteins (28, 32).
Currently available in vitro and in vivo data are in line with an
anti-inflammatory role for PADs in local acute inflammation by
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citrullinating and thereby inactivating chemokines, such as
CXCL5, CXCL8, CXCL10, CXCL11, and CXCL12, and, conse-
quently, dampening leukocyte migration (33). In addition,
chemokine citrullination may be important, in particular, in mi-
crobial defense mechanisms, since peptidylarginine deiminating
activity has been reported in one prokaryotic organism, Porphy-
romonas gingivalis (25, 34). It is well-known that an outgrowth of
P. gingivalis within the periodontal pocket is associated with peri-
odontitis, an inflammatory disorder characterized by periodontal
tissue destruction, loss of alveolar bone, and, eventually, tooth
loss. In contrast to other mammalian PADs, PAD of P. gingivalis
(PPAD) preferentially citrullinates C-terminal arginine residues
and is also able to convert free Arg into Cit. In contrast to mam-
malian enzymes, PPAD deiminates peptidylarginine residues in a
calcium-independent manner (25, 34, 35). Its ammonia-produc-
ing properties are well studied as a response to acidic cleansing
cycles in the mouth (34, 36, 37). Though the substrates for the
action of PPAD are unidentified and the exact role of PPAD in
assisting the bacterium in circumventing the host immune de-
fense is unknown, PPAD has been suggested to function as an
additional virulence factor (25, 34). In the context of an innate
immune response, chemokine citrullination by PPADmay estab-
lish a negative feedback on local leukocyte-mediated inflamma-
tion and, hence, bacterial clearance. Together with inflammation-
associated and PPAD-exerted citrullination of host proteins, this
may contribute to the breakdown of immunotolerance to citrul-
linated epitopes and the eventual development of rheumatoid ar-
thritis (RA) (38).
Gingipains, including arginine-specific gingipains (RgpA and
RgpB) and the lysine-specific gingipain (Kgp), are considered to
be essential virulence factors of P. gingivalis (39). These protein-
ases are either cell surface associated or secreted. Gingipains play
an important role in the evasion and dysregulation of the host’s
immune response by the degradation of proinflammatory cyto-
kines, complement factors, antimicrobial peptides, and immuno-
globulins at the site of infection (39–41). Since both PPAD and
gingipains were found to significantly contribute to P. gingivalis
virulence, we investigated whether PTM of chemokines by these
enzymes represents a way by which P. gingivalis regulates the in-
flammatory response.
MATERIALS AND METHODS
Reagents and materials. The 77 amino acid forms of the chemokines
CXCL8, CXCL10, and macrophage inflammatory protein 1 (MIP-1;
CCL3) were obtained from PeproTech (Rocky Hill, NJ).
N-Acetylo-L-Arg, L-Cit, 2,3-butanedione monoxime, thiosemicarba-
zide, antipyrine, and 2,3-butanedione (99.4% GC content) were pur-
chased from Sigma-Aldrich (St. Louis, MO).
RgpB was purified as previously described (42, 43). To obtain PPAD,
P. gingivalisW83was engineered to secrete a soluble form of PPADwith a
C-terminal hexahistidine affinity tag using the same molecular strategy
reported previously for the RgpB protease in the mutant 662i6H (44).
Subsequently, PPAD was separated from the culture medium via ion-
exchange and gel filtration chromatography, as described for the purifi-
cation of soluble Kgp from the growthmedium (45). Briefly, bacteria were
removed by centrifugation, and proteins in themediumwere precipitated
with acetone, resuspended in phosphate buffer (pH 6.5), dialyzed, and
passed through a DE-52 column (Whatman, GE Healthcare, Pittsburgh,
PA) to remove excess hemin. The flowthrough was dialyzed against 50
mM Tris-HCl, 0.02% NaN3, pH 8.0, and loaded on a Mono Q column
(GE Healthcare). Adsorbed proteins were eluted with an NaCl gradient,
and fractions containing PPAD activity were pooled. The final PPAD
purification was achieved by gel filtration chromatography using a Super-
dex 75 column (GE Healthcare). The purity of PPAD was evaluated by
SDS-PAGE, followed by silver staining. Gingipain-specific inhibitors
KYT-1 and KYT-36 were obtained from PeptaNova (Sandhausen, Ger-
many).
Biotinylated CXCL8 (biotCXCL8) was synthesized, folded, and puri-
fied in the Laboratory of Molecular Immunology at the Department of
Microbiology and Immunology, Rega Institute. Briefly, CXCL8 was syn-
thesized as previously described (23). After removal of the final 9-fluore-
nylmethoxy carbonyl (Fmoc) group of the most NH2-terminal amino
acid, the free NH2 terminus was biotinylated with biotin-p-nitrophenyl
ester (Novabiochem, Darmstadt, Germany) on a 433A solid-phase pep-
tide synthesizer (Applied Biosystems, Foster City, CA) using standard
coupling chemistry. The synthetic biotinylated CXCL8 peptide was
cleaved from the resin, purified, folded, and repurified as described for
intact CXCL8 (23). The purity of biotinylated CXCL8 was confirmed by
ion trap mass spectrometry after purification using reverse-phase high-
pressure liquid chromatography (RP-HPLC) (Fig. 1).
Strains and culture conditions. P. gingivalisATCC 33277 was used as
a reference strain. Five capsule-typed strains (K1 to K5) (46, 47) and five
clinical isolates with nontyped capsule (Pg1 to Pg5) (48) were included in
the analysis (Table 1). P. gingivalis strains were grown on blood agar plates
(Oxoid, Basingstoke, United Kingdom) supplemented with 5 g/ml he-
min (Sigma-Aldrich), 1 g/ml menadione, and 5% sterile horse blood
(Biotrading, Keerbergen, Belgium). Bacteria were collected from blood
agar plates, transferred to 10 ml tryptone soy broth (Oxoid), and incu-
bated overnight at 37°C in an anaerobic atmosphere. The bacterial con-
centration was adjusted by measuring the optical density at 600 nm to
obtain bacterial suspensions with starting concentrations of 5 107 CFU/
ml. Supernatants were obtained by centrifuging for 3 min at 13,200 rpm.
PPAD activity assay. PPAD activity was tested by a colorimetric
method for the determination of enzymatically produced L-Cit as de-
scribed by Knipp and Vasak (49). A standard for L-Cit ranging from 0 to
1,200 M was prepared in 0.1 M Tris-HCl buffer (pH 7.5), and subse-
quently, 50 l was pipetted in a 96-well plate. Ten microliters of each
sample was mixed with 40 l 0.1 M Tris-HCl buffer (pH 7.5) supple-
mented with 10 mM N-acetylo-L-Arg before pipetting into the 96-well
plate. The 96-well plate containing the standard and samples was incu-
bated for 1 h at 37°C. Finally, 150 l of freshly prepared citrulline detec-
tion reagent {1 volume of solution A [80mM2,3-butanedionemonoxime
and 2 mM thiosemicarbazide] and 3 volumes of solution B [3 M H3PO4,
6MH2SO4, and 2mMNH4Fe(SO4)2·12H2O]}was added, and the 96-well
plate was incubated for 15min at 95°C. Cit was detected bymeasuring the
absorbance at 535 nm.
In vitro incubation of CXCL8 and CCL3 with PPAD. CXCL8 or
CCL3 was incubated with purified activated PPAD and gingipain-specific
inhibitors (10 M KYT-1 and KYT-36) for 1.5 h at 37°C at an enzyme-
substrate (E/S) molar ratio of 1/10 and a substrate concentration of 7.6
M. Incubations with PPAD were carried out in 50 mM Tris-HCl, 150
mMNaCl (pH 7.8). Enzymatic citrullination was stopped with 0.1% (vol/
vol) trifluoroacetic acid (TFA).
In vitro incubation of CXCL8, CXCL10, and [Cit5]CXCL8 with gin-
gipains. RgpB was first activated for 10 min at 37°C in activation buffer
(0.2 MHEPES, 10 mM L-Cys, 10 mMCaCl2, pH 8). CXCL8, CXCL10, or
citrullinated CXCL8 ([Cit5]CXCL8) was then incubated with activated
RgpB for 1 h at 37°C at an E/S molar ratio of 1/1 and a substrate concen-
tration of 1 M. Incubations with RgpB were carried out in 20 mM Tris-
HCl, 5mMCaCl2, 0.1MNaCl (pH 8). Enzymatic processing was stopped
with 0.1% (vol/vol) TFA and investigated by Edman degradation on a 491
Procise cLC protein sequencer (Applied Biosystems, Foster City, CA).
PTM of CXCL8 and CXCL10 by different P. gingivalis strains. Bac-
terial suspensions with starting concentrations of 5  107 CFU/ml were
first grown for 24 h in 96-well plates (200l/well) at 37°C in an anaerobic
atmosphere. Then, the strains were treated with 5 g/ml CXCL8 or
Moelants et al.
2512 iai.asm.org Infection and Immunity
 o
n
 M
ay 14, 2014 by KU LEUVEN
http://iai.asm
.org/
D
ow
nloaded from
 
CXCL10 for 2 h, and the supernatantswere harvested and stored at20°C
after centrifuging for 3 min at 13,200 rpm.
To investigate the potential binding of CXCL8 to the bacterial mem-
brane, strains were treated with 500 ng/ml biotCXCL8 and protease in-
hibitor (cOmplete ULTRA, Mini, EDTA-free EASYpack; Roche) supple-
mentedwith 5mMEDTA for 2 h. Supernatants and pellets were harvested
and stored at20°C after centrifuging for 3 min at 13,200 rpm.
Proteolytic processing of CXCL8 and CXCL10 by secreted versus
membrane-bound gingipains. Bacterial suspensions of 5 107 CFU/ml
were cultured for 24 h in 96-well plates (200 l/well) at 37°C in an anaer-
obic atmosphere, and supernatants were harvested. To examine the pro-
teolytic processing of chemokines by P. gingivalis proteases, CXCL8 and
CXCL10 were incubated with 5 l of supernatants or with the complete
bacterial culture at 37°C. Samples were separated by SDS-PAGE using
14% ProSieve50 gels (Lonza, Basel, Switzerland) with a Tris-Tricine elec-
trode buffer (0.1MTris, 0.1MTricine, 0.1% SDS). Gels were blotted onto
a polyvinylidene difluoride (PVDF) membrane that was subsequently
stained using Coomassie brilliant blue. Finally, the NH2-terminal protein
sequences of the protein bands visible on the blot were determined by
Edman degradation on a 491 Procise cLC protein sequencer (Applied
Biosystems).
Detection of total CXCL8, biotCXCL8, and CXCL10. The levels of
human CXCL8 and CXCL10 were quantified by specific sandwich en-
zyme-linked immunosorbent assays (ELISAs) (50–52).
For human CXCL8, a 96-well plate was coated with goat polyclonal
anti-human CXCL8 antibody generated in our laboratory (53), followed
by blocking with phosphate-buffered saline (PBS; pH 7.4) containing
0.1% (wt/vol) casein and 0.05% (vol/vol) Tween 20. Human CXCL8
bound to the coating antibodywas detectedwithmousemonoclonal anti-
human CXCL8 antibody (R&D Systems, Abingdon, United Kingdom),
followed by a secondary peroxidase-conjugated anti-mouse IgG (Jackson
ImmunoResearch Laboratories,West Grove, PA). Peroxidase activity was
FIG 1 Ion trap mass spectra of purified synthetic biotinylated CXCL8. CXCL8 was synthesized using 9-fluorenylmethoxy carbonyl (Fmoc) chemistry and
purified using RP-HPLC. After removal of the final Fmoc group of the most NH2-terminal amino acid, the free NH2 terminus was biotinylated with biotin-p-
nitrophenyl ester using standard coupling chemistry. TheMr of the purified synthetic biotCXCL8was determined by deconvolution of themultiple charged ions
in the raw spectra. As expected, the Mr of biotCXCL8 differed by almost exactly 226.3 mass units (Mr  9,144.8) from that of the unmodified CXCL8 (Mr 
8,918.3).
TABLE 1 P. gingivalis strains useda
Strain Strain code
Disease
type
Probing
depth (mm)
Laboratory strain
ATCC 33277
NK NK NK
Capsule-typed strains
K1 to K5
NK NK NK
Clinical isolates
Pg1 C1-IIIa CAP 8.3
Pg2 C7-1 RPP 7.7
Pg3 R33-2 Res 4.0
Pg4 T9-6 CAP 8.0
Pg5 T1-IIIb CAP 7.3
a NK, not known; CAP, chronic adult periodontitis; RPP, rapidly progressive
periodontitis; Res, resistance to periodontitis.
Processing of Chemokines by Porphyromonas gingivalis
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quantified bymeasuring the conversion of 3,3=,5,5=-tetramethylbenzidine
(TMB; Sigma-Aldrich) at 450 nm.
To measure biotCXCL8, plates were coated with goat polyclonal anti-
human CXCL8 antibody (see above), and biotCXCL8 was detected with
peroxidase-conjugated streptavidin (R&D Systems).
The sandwich ELISA for human CXCL10 consisted of mouse mono-
clonal anti-human CXCL10 as the coating antibody, biotinylated rabbit
polyclonal anti-human CXCL10 as the detecting antibody, and peroxi-
dase-conjugated streptavidin as the secondary reagent (all were from
R&D Systems).
Detection of citrullinated chemokines. The procedure to chemically
modify and quantify a citrulline-containing protein of interest was per-
formed as described before (54). Briefly, peptidylcitrulline residues in
samples were first chemically modified by addition of 50 mM antipyrine,
16% (vol/vol) TFA, and 12.5 mM 2,3-butanedione (55), followed by in-
cubation for 2 h at 37°C in the dark. Then, the strongly acidic reaction
mixture was dialyzed against PBS containing 0.05% Tween 20 (pH 7.4)
overnight at room temperature and protected from light using Slide-A-
Lyzer Mini dialysis units (Pierce, Rockford, IL).
To detect [Cit5]CXCL8, a specific sandwich ELISA was developed
(54). A 96-well plate was coated with mouse monoclonal anti-human
CXCL8 antibody (R&DSystems), followed by blockingwith PBS contain-
ing 0.1% casein and 0.05%Tween 20. Human [Cit5]CXCL8 in chemically
modified samples was detected by specific rabbit antibodies against chem-
ically modified citrulline residues and by a secondary peroxidase-conju-
gated anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories).
Peroxidase activity was quantified by measuring the conversion of TMB
(Sigma-Aldrich) at 450 nm. Citrullination of CCL3 was detected in a
similar way by using a mouse monoclonal anti-human CCL3 antibody
(R&D Systems) instead of the mouse monoclonal anti-human CXCL8
antibody.
In addition, for the in vitro incubation of CXCL8 with PPAD, the
NH2-terminal sequences of CXCL8 were determined by Edman degrada-
tion on a 491 Procise cLC protein sequencer (Applied Biosystems) to
verify if citrullination occurred on the more NH2-terminally located Arg
residues.
RESULTS
Enzymatic modification of chemokines by PPAD and gin-
gipains. Before incubating chemokines with PPAD in vitro, the
activation of the enzyme by different reducing agents was evalu-
ated with a PPAD activity assay (49). In contrast to 10 mM re-
duced glutathione, both L-cysteine (L-Cys) (10 mM, 30 mM, and
90 mM) and dithiothreitol (DTT; 5 mM) were able to activate
PPAD (Fig. 2).
Upon incubation of intact CXCL8 with activated PPAD (30
mML-Cys) at an E/Smolar ratio of 1/10 for 1.5 h, no citrullination
was detected by the specific ELISA. However, NH2-terminal se-
quencing revealed about 10% citrullination on the most NH2-
terminal Arg but no citrullination of the Arg in the ELR motif of
CXCL8. Besides CXCL8, CCL3 is also reported to be an important
inflammatory chemokine mediator in periodontitis (56, 57).
However, upon incubation of intact CCL3 with activated PPAD
(30 mM L-Cys) at an E/S molar ratio of 1/10 for 1.5 h, no citrul-
lination could be detected by the specific ELISA tomeasure citrul-
linated CCL3. In contrast to CXCL8, the NH2 terminus of CCL3
contains no Arg, soNH2-terminal sequencing was not performed.
Activated RgpB efficiently cleaved CXCL8 and CXCL10 in vitro.
After 30min, no intact CXCL8was present anymore, as onlyNH2-
terminally processed forms of CXCL8 (e.g., forms of CXCL8 con-
sisting of amino acids 6 to 77, 12 to 77, and 32 to 77 [the 6-77,
12-77, and 32-77 forms, respectively]) were detected. Also for
CXCL10, cleavage occurred very rapidly, as after 5 min of incuba-
tion, less than 25% intact chemokine could be detected (data not
shown). Interestingly, citrullination of CXCL8 prevented this
chemokine from being cleaved by RgpB. This confirms the high
specificity of RgpB for ArgOX bonds.
Enzymatic citrullination of chemokines by P. gingivalis.
CXCL8 andCXCL10were incubatedwith full cultures of different
P. gingivalis strains for 2 h. Subsequently, the total amounts of
CXCL8 and CXCL10 were determined by standard ELISA and
citrullinated chemokine was quantified by a specific sandwich
ELISA, as recently described (54).
CXCL8 was recovered after incubation with most tested
strains; however, only a small amount of CXCL8 (up to 5%) was
detected to be citrullinated in samples for all tested strains of P.
gingivalis (Fig. 3). At first, an obvious explanation for this could be
the NH2-terminal cleavage of CXCL8 at Lys8 by Kgp, which po-
tentially removes the first 8 amino acids, including the Arg in
position 5, i.e., the Arg which is most susceptible to citrullination
by human PAD2 and PAD4 (8). However, the citrullination levels
detected upon incubation with PPAD in vitro were also very low.
Therefore, a more plausible reason for the low citrullination of
CXCL8 for all tested strains of P. gingivalis is that PPAD citrulli-
nates CXCL8 inefficiently.
To further investigate whether inflammatory chemokines be-
come citrullinated by PPAD, we selected CXCL10, which is a ma-
jor attractant for natural killer cells and activated T cells and is
citrullinated by human PAD2 and PAD4 but which has no NH2-
terminal lysine residues (Lys [K]). Thus, the NH2 terminus of
CXCL10 (NH2-
1VPLSRTVRCT10) is resistant to proteolysis by
Kgp, leavingArg5 andArg8 available for citrullination byPPAD. In
this case, however, only very low levels of CXCL10 were recovered
immediately after treatmentwithP. gingivalis and noCXCL10was
detected for any strain after 2 h of incubation. This suggests that P.
gingivalis directly interacts with CXCL10 by binding, degrading,
or internalizing the chemokine. When CXCL10 was incubated
with supernatants of P. gingivalis, already after 5 min, no intact
CXCL10 was present, indicating very fast degradation of CXCL10
by P. gingivalis (see below).
FIG 2 Activation of PPAD by different reducing agents. Before incubation of
CXCL8 with PPAD in vitro, the activation of the enzyme by different reducing
agents was evaluated with the PPAD activity assay (49). The mean enzymatic
activity (U/mg enzyme) SEM is presented for each activator (n 6). Statis-
tical analysis was performed using the Mann-Whitney U test. ***, P 	 0.001
for the comparison with the control; ‡, P 	 0.001 for the comparison with
glutathione.
Moelants et al.
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Proteolytic cleavage of chemokines by P. gingivalis. CXCL8
was incubated with different P. gingivalis strains for 2 h, and
CXCL8 levels weremeasured by ELISA. For all strains, the amount
of CXCL8 still present after 2 h was lower than the initial quantity
added, indicating that clearance of CXCL8 from the bacterial me-
dium occurred (Fig. 4). However, some strains seemed more effi-
cient in degrading CXCL8, since for strains Pg1, Pg2, and K1 to
K4, only a very small amount of CXCL8 was detected after 2 h.
Samples in which CXCL8was still present after 2 h were examined
by gel electrophoresis and NH2-terminal sequencing (Table 2).
Besides intact CXCL8, three NH2-terminally processed forms of
CXCL8, i.e., the more potent variants consisting of the CXCL8
from amino acids 6 to 77 [CXCL8(6-77)] and CXCL8(9-77) and
the further truncated variant CXCL8(16-77), could be detected,
indicating that NH2-terminal truncation by cleavage at Arg
5 and
Lys8 precedes further degradation of the chemokine. To investi-
gate the potential binding of CXCL8 to the bacterial membrane,
biotCXCL8 was incubated with different strains and protease in-
hibitor for 2 h. CXCL8 was specifically biotinylated at the NH2
terminus by chemical synthesis. Thus, modification of the side
chains of Lys was avoided and potential cleavage sites for Kgp
remained unaltered. Supernatants and bacteria were harvested,
and the biotCXCL8 in both fractionswasmeasured by ELISA (Fig.
5). The amount of biotCXCL8 recovered in the cell pellets was
negligible compared to the chemokine levels present in the super-
natants. These data confirm the importance of the degradation by
FIG 3 Citrullination of CXCL8 by different clinical isolates of P. gingivalis.
Bacterial suspensions with starting concentrations of 5  107 CFU/ml were
first grown for 24 h at 37°C in an anaerobic atmosphere. Then, the strains were
treated with 5g/ml CXCL8 for 2 h and the supernatants were harvested. The
levels of humanCXCL8were quantified by ELISA. The amount of citrullinated
CXCL8 was determined by combined chemical modification and ELISA, as
described before (54). The mean percent citrullination of CXCL8  SEM is
presented for each strain (n 3). X, citrullination levels which are below the
detection limit (0.4 ng/ml). Statistical analysis was performed using theMann-
Whitney U test. *, P	 0.05 for the comparison with laboratory strain ATCC
33277.
FIG 4 Recovery of CXCL8 after incubation with different clinical isolates and
capsule-typed strains of P. gingivalis. Bacterial suspensions with starting con-
centrations of 5 107 CFU/ml were first grown for 24 h at 37°C in an anaer-
obic atmosphere. Then, the strains were treated with 5 g/ml CXCL8 for 2 h
and the supernatants were harvested. The levels of human CXCL8 were quan-
tified by ELISA. The mean CXCL8 recovery SEM after 2 h is presented for
each strain (n 3). Statistical analysis was performed using the Mann-Whit-
ney U test. *, P	 0.05 for the comparison with laboratory strain ATCC 33277.
TABLE 2 NH2-terminally processed forms of CXCL8 after 2 h of
incubation with different P. gingivalis strains detected by Edman
degradation
Strain
% of the following NH2-terminally
processed forms of CXCL8:
1-77 6-77 9-77 16-77
Laboratory strain ATCC 33277 NDa ND 50 50
Capsule-typed strains
K1 ND ND ND ND
K2 ND ND ND ND
K3 ND ND ND ND
K4 ND ND ND ND
K5 39 32 29 ND
Clinical isolates
Pg1 ND ND ND ND
Pg2 ND ND ND ND
Pg3 ND ND 100 ND
Pg4 ND ND 100 ND
Pg5 ND ND 100 ND
a ND, not detectable.
FIG 5 Levels of biotinylated CXCL8measured in supernatants and cell pellets
of P. gingivalis. Bacterial suspensions with starting concentrations of 5  107
CFU/ml were first grown for 24 h at 37°C in an anaerobic atmosphere. Then,
the strains were treated with 500 ng/ml biotCXCL8 and protease inhibitor for
2 h. Supernatants () and cell pellets () were harvested, and the levels of
biotCXCL8were quantified byELISA. ThemeanCXCL8 recovery SEMafter
2 h is presented for each strain (n  2). Control 1, TSB medium with
biotCXCL8 and protease inhibitor incubated for 2 h; control 2, Pg2 treated
with 500 ng/ml biotCXCL8 without protease inhibitor for 2 h; ND, not detect-
able (	2 ng/ml).
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proteases (e.g., gingipains) (andnot by binding to the bacterial cell
surface) in the removal of CXCL8 from the medium.
When CXCL8 was incubated for 2 h with supernatants of P.
gingivalis, cleavage clearly occurred (Fig. 6). In contrast to the
difference in cleavage measured by ELISA for CXCL8 incubated
with P. gingivalis cultures (Fig. 4), no quantitative difference in
processing of CXCL8 by cell-free culture supernatants of strains
ATCC 33277, Pg1 to Pg5, and K1 to K5 could be seen (Fig. 6).
Sequencing of the CXCL8 incubated with the supernatant showed
that CXCL8 is processed first into its more potent 6-77 and 9-77
forms before being totally degraded. The highly active truncated
CXCL8(9-77) was clearly the most dominant form found in all
incubations (57% 5.4%).
Also, CXCL10 was incubated with different P. gingivalis strains
for 2 h, and CXCL10 levels were detected by ELISA. However,
none of the CXCL10 was recovered when it was incubated for 2 h
withwhole bacteria (see above).WhenCXCL10was incubated for
5 min, 30 min, or 2 h with supernatants of P. gingivalis, CXCL10
was detectable only after 5 min, as evidenced by gel electrophore-
sis, blotting, and Edman degradation. However, even after 5 min
of incubation, no intact CXCL10was detected, indicating fast deg-
radation of CXCL10 by P. gingivalis. Two processed forms of
CXCL10 (i.e., the 23-77 and 27-77 forms) were detected.
DISCUSSION
Enzymatic citrullination of chemokines by P. gingivalis. PTMs
affect the biological activity of cytokines and chemokines (2, 4,
58). Recently, citrullination, a new PTM of chemokines, has been
discovered (8, 21). The conversion of peptidylarginine to pepti-
dylcitrulline is performed by the mammalian PAD enzymes (25).
The biological function of chemokines is influenced by citrullina-
tion. Citrullination ofCXCL8byPADprotects CXCL8 fromNH2-
terminal activation by thrombin and plasmin, reduces its glycos-
aminoglycan binding properties, moderately alters binding of
CXCL8 to the CXC chemokine receptors CXCR1 and CXCR2,
reduces CXCL8-induced neutrophil extravasation to the perito-
neal cavity, and increases the ability of chemokines to mobilize
neutrophils to the blood circulation (8, 59). Not only eukaryotes
but also the prokaryotic organism P. gingivalis are known to ex-
press PAD. Colonization of a biofilm on the tooth surface by P.
gingivalis and its subgingival proliferation lead to immune reac-
tions eroding teeth-supporting tissues. Recently, a potential cor-
relation between periodontitis and the autoimmune disease rheu-
matoid arthritis (RA),which is linked to protein citrullination, has
been proposed (32, 60–62). It is suggested that PPAD is responsi-
ble for the citrullination of proteins like fibrinogen and-enolase,
leading to the production of anti-citrullinated peptide antibodies
(ACPAs) and immune complexes. This results in inflammation
and may finally cause chronic RA (63–65). The occurrence of
chemokine citrullination by bacterial PPAD, however, was not
investigated until now. Therefore, we hypothesized that chemo-
kines are possibly citrullinated by PPADduring P. gingivalis infec-
tion. In the gingival crevicular fluid of periodontitis patients, how-
ever, CXCL8 is present only in pg/ml concentrations (66) in a
milieu containing other proteins and peptides at mg/ml concen-
trations, which makes detection of [Cit5]CXCL8 with the cur-
rently available techniques a great challenge. Future studies
should elucidate if CXCL8 is citrullinated by PPAD in vivo by the
detection of [Cit5]CXCL8 in gingival crevicular fluid of periodon-
titis patients.
We observed only a low level of enzymatic citrullination of
CXCL8upon incubationwith purified PPADat an E/Smolar ratio
of 1/10. In comparison, human PAD2 and PAD4 were able to
citrullinate 50% of the NH2-terminal Arg in CXCL8 in 10 min at
an E/Smolar ratio of 1/200 (8). Also for CCL3, another important
inflammatory chemokine mediator in periodontitis (56, 57), no
citrullination could be detected. Furthermore, no significant cit-
rullination of CXCL8 could be measured when testing several P.
gingivalis strains by a recently developed method for detection of
citrullinated proteins (54). In contrast, rapid cleavage of CXCL8
by the gingipains expressed by P. gingivalis occurred. The process-
ing of CXCL8(1-77) into CXCL8(9-77) by secreted gingipains re-
moves theNH2-terminal octapeptide, including the Arg
5, which is
the residue known to be citrullinated by human PAD (8). Another
potential explanation for the failure to detect [Cit5]CXCL8 can be
related to the low citrullinating activity of PPAD on Arg5 of
CXCL8. Indeed, previous research indicated that PPAD preferen-
tially targets COOH-terminal Arg, in contrast to human PAD,
which efficiently citrullinates NH2-terminal or internal Arg (34).
However, as only 	5% citrullination was detected by ELISA,
COOH-terminal citrullination of CXCL8 by PPAD seems to be
inefficient.
Proteolytic cleavage of chemokines by P. gingivalis. As pre-
viously reported, CXCL8 was efficiently processed upon incuba-
tion with gingipains (RgpB) in vitro (67, 68). Upon incubation
with different P. gingivalis strains, cleavage was detected for all
strains. However, some strains were more efficient in degrading
CXCL8, as for Pg1, Pg2, and K1 to K4, no CXCL8 was detected
after 2 h. Clearance of CXCL8 from the medium can be caused by
degradation by gingipains or by the binding to the bacterial mem-
brane (and internalization). Our data, however, demonstrate the
more important role of enzymatic degradation in removing
CXCL8 from themedium compared to the importance of binding
to the bacterial membrane. CXCL8 was shown to be first con-
verted to more potent forms by purified gingipains, followed by
total degradation (68). This report further demonstrates the con-
secutive activation and destruction of CXCL8 by incubation with
different P. gingivalis strains. Earlier studies have shown the rela-
tion between bacterial surface structures and the virulence of dif-
ferent P. gingivalis strains, indicating that bacteria with large hy-
drophilic capsules are the most virulent ones (69–71). These
FIG 6 Cleavage of CXCL8 by the supernatants of different clinical isolates and
capsule-typed strains of P. gingivalis. Bacterial suspensions with starting con-
centrations of 5  107 CFU/ml were grown for 24 h at 37°C in an anaerobic
atmosphere, and supernatants were harvested. CXCL8 (1 g) was incubated
with 5l of the supernatants of ATCC 33277, Pg1 to Pg5, and K1 to K5 for 2 h
at 37°C. To examine proteolytic processing of chemokines, samples and un-
treated CXCL8 (control) were separated by SDS-PAGE, transferred to a PVDF
membrane, and stained with Coomassie brilliant blue.
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studies demonstrated that strains K1 (HG66/W83) and K2
(HG184) display a more hydrophilic character than strain ATCC
33277. This might explain the disappearance of CXCL8 from the
mediumby binding to the bacterial capsule of these strains. Clear-
ance of CXCL8 from the surrounding medium represents a pow-
erful mechanism to downregulate the host’s immune response. In
this respect, strains Pg1, Pg2, andK1 toK4 can be consideredmore
virulent than the other tested strains, because after 2 h no CXCL8
remained present in the bacterial medium.
Analysis of samples still containing CXCL8 after 2 h of incuba-
tion revealed, besides intact CXCL8, three processed forms of
CXCL8 (i.e., the 6-77, 9-77, and 16-77 forms). This indicates
NH2-terminal cleavage after Arg
5 and Lys8, possibly by Lys- and
Arg-specific gingipains, before further degradation. Both 6-77 and
9-77 represent forms ofCXCL8more active than intact CXCL8. In
the formmissing the 15most NH2-terminal amino acids, the ELR
motif is removed, implying a loss of receptor internalization and
biological activity. The generation of more potent CXCL8 forms
seems to contradict the role of gingipains in the evasion and dys-
regulation of the host’s immune response by the degradation of
the host’s proinflammatory cytokines at the site of infection (39–
41). However, also for other human proteins like the human com-
plement factors, a biphasic effect of gingipains from P. gingivalis
has been suggested (72–74). Not only are gingipains able to de-
grade complement factors, rendering P. gingivalis resistant to the
antibacterial activity of complement, but also they initially in-
crease complement activation. The basal level of inflammation
caused by this activation is suggested to supply the bacteria with
nutrients and might allow colonization (73).
In contrast to clear variations in the ability of full cultures of
different strains of P. gingivalis to cleave CXCL8, no such differ-
ences were found for cell-free culture supernatants (Fig. 6). A
possible explanation is that secreted gingipain activity is modu-
lated by components of the cell surface. Alternatively, the local
concentration of enzymes in the microenvironment of the mem-
brane highly surpasses the concentration of soluble gingipains in
the medium. The latter is supported by the observation that, ex-
cept for P. gingivalis strain HG66, all other strains retain the ma-
jority of gingipains on the cell surface (75–77). Moreover, CXCL8
was processed into its more active 6-77 and 9-77 forms by the
gingipains in the supernatants. CXCL8(9-77) was clearly themost
dominant form found in all incubations. These results confirm
previous observations that gingipains in the soluble form are able
to initially convert CXCL8 tomore potent species truncated at the
amino terminus, followed by slow degradation and destruction of
chemokine biological activity (68).
In contrast to CXCL8, citrullinated CXCL8 is not cleaved by
RgpB. Since both human PAD2 and PAD4 together with CXCL8
are present in inflamed periodontal tissue (78), citrullination
might protect the chemokine from being processed tomore active
forms, representing a mechanism to dampen the inflammation.
Recently, it has been shown that P. gingivalis can inhibit the pro-
duction of CXCL10 by epithelial cells, highlighting the immune-
disruptive potential of this bacterium (79). Our data show a very
fast degradation of CXCL10 by P. gingivalis. Two processed forms
of CXCL10 (i.e., the 23-77 and 27-77 frosm) were present after 5
min of incubation with supernatants of the bacteria. These forms
might arise from cleavage by secreted gingipains of P. gingivalis
present in the supernatants, as residues 22 and 26 are, respectively,
Arg and Lys.
At high concentrations (micromolar range) CXCL10 is known
to be a chemokine with antimicrobial peptide-like properties for
Escherichia coli and Listeria monocytogenes allowing it to bind to
cells and induce cell death (80). However, density measurements
(data not shown) indicate that the viability of the tested P. gingi-
valis strains was not influenced by the addition of CXCL10 (5
g/ml) to bacterial cultures for 2 h. It is possible that CXCL10 is
not able to bind to P. gingivalis and, consequently, cause cell death
because of its rapid degradation by gingipains secreted in the me-
dium (as shown in Results). In addition, the concentrations
CXCL10 that we added were lower than the reported concentra-
tions (80, 81).
In conclusion, this study could not confirm the citrullination
of CXCL8 and CXCL10 by PPAD. However, the efficient post-
translational modification of CXCL8 and CXCL10 by gingipains
of P. gingivalis was shown.
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